4-butyrolactone has been researched along with Osteoarthritis in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Del Castillo, J; Delsart, A; Drag, M; Frezier, M; Lussier, B; Martel-Pelletier, J; Moreau, M; Otis, C; Pelletier, JP; Troncy, E | 1 |
| Beale, B; Jarudecha, T; Kashemsant, N; Kwananocha, I; Lascelles, BDX; Lekcharoensuk, C; Peirone, B; Vijarnsorn, M | 1 |
| Ding, X; Feng, Z; Hu, Z; Li, X; Ni, W; Wu, A; Wu, D; Xuan, J; Zheng, G | 1 |
| Chen, Q; Chen, Z; Deng, M; Li, Y; Liu, S; Ma, Y; Ming, J; Zhang, Y; Zhou, Y | 1 |
| Budsberg, SC; Punke, JP; Reynolds, LR; Speas, AL | 1 |
| Joubert, KE | 1 |
| Lecoindre, O; Pepin-Richard, C | 1 |
| Asimus, E; Autefage, A; Palissier, FM; Pepin-Richard, C | 1 |
| Boston, RC; Carithers, DS; Orsini, JA; Ryan, WG | 1 |
| Carithers, D; Moldave, K; Ryan, WG | 2 |
| Alva, R; Bell, L; Brooks, KC; Case, J; Conzemius, M; Drag, M; Fleishman, C; Gordon, W; Hanson, PD; Romano, D; Schuessler, J; Shelley, B; Sifferman, R | 1 |
| Fleishman, C; Hanson, PD; Pollmeier, M; Toulemonde, C | 1 |
| Overgaauw, P | 1 |
| Alva, R; Bertone, AL; Doucet, MY; Hanson, PD; Hendrickson, D; Hughes, F; Kunkle, B; Macallister, C; McClure, S; Reinemeyer, C; Romano, D; Rossier, Y; Sifferman, R; Vrins, AA; White, G | 1 |
8 trial(s) available for 4-butyrolactone and Osteoarthritis
| Article | Year |
|---|---|
The effectiveness of marine based fatty acid compound (PCSO-524) and firocoxib in the treatment of canine osteoarthritis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Dog Diseases; Dogs; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Unsaturated; Female; Gait; Male; Osteoarthritis; Pain; Pain Measurement; Prospective Studies; Sulfones | 2019 |
Effects of firocoxib, meloxicam, and tepoxalin on prostanoid and leukotriene production by duodenal mucosa and other tissues of osteoarthritic dogs.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Duodenum; Female; Intestinal Mucosa; Leukotrienes; Male; Meloxicam; Osteoarthritis; Prostaglandins; Pyrazoles; Sulfones; Synovial Fluid; Thiazines; Thiazoles | 2008 |
The effects of firocoxib (Previcox) in geriatric dogs over a period of 90 days.
Topics: 4-Butyrolactone; Aging; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Chemical Analysis; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Osteoarthritis; Pain; Severity of Illness Index; Sulfones; Treatment Outcome | 2009 |
Evaluation of oral administration of firocoxib for the management of musculoskeletal pain and lameness associated with osteoarthritis in horses.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Cyclooxygenase 2 Inhibitors; Female; Horse Diseases; Horses; Lameness, Animal; Male; Musculoskeletal Pain; Osteoarthritis; Pain Management; Sulfones | 2012 |
Clinical effectiveness and safety of a new NSAID, firocoxib: a 1,000 dog study.
Topics: 4-Butyrolactone; Age Factors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Female; Male; Osteoarthritis; Safety; Sex Factors; Sulfones; Treatment Outcome | 2006 |
Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Etodolac; Female; Lameness, Animal; Male; Osteoarthritis; Range of Motion, Articular; Safety; Sulfones; Treatment Outcome | 2006 |
Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Dog Diseases; Dogs; Double-Blind Method; Female; Male; Osteoarthritis; Sulfones; Tablets; Treatment Outcome | 2006 |
Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Female; Horse Diseases; Horses; Lameness, Animal; Male; Osteoarthritis; Phenylbutazone; Range of Motion, Articular; Severity of Illness Index; Sulfones; Time Factors; Treatment Outcome | 2008 |
7 other study(ies) available for 4-butyrolactone and Osteoarthritis
| Article | Year |
|---|---|
Development of Two Innovative Performance-Based Objective Measures in Feline Osteoarthritis: Their Reliability and Responsiveness to Firocoxib Analgesic Treatment.
Topics: 4-Butyrolactone; Analgesics; Animals; Cats; Osteoarthritis; Reproducibility of Results; Sulfones | 2022 |
The Protective Effect of Ligustilide in Osteoarthritis: An in Vitro and in Vivo Study.
Topics: 4-Butyrolactone; ADAMTS5 Protein; Aged; Animals; Cell Survival; Cells, Cultured; Chondrocytes; Cyclooxygenase 2; Cytokines; Disease Models, Animal; Humans; Interleukin-1beta; Male; Matrix Metalloproteinase 3; Mice; Mice, Inbred C57BL; Middle Aged; NF-KappaB Inhibitor alpha; Nitric Oxide Synthase Type II; Osteoarthritis | 2018 |
Ligustilide attenuates nitric oxide-induced apoptosis in rat chondrocytes and cartilage degradation via inhibiting JNK and p38 MAPK pathways.
Topics: 4-Butyrolactone; Animals; Apoptosis; Cartilage, Articular; Cell Nucleus Shape; Cell Survival; Chondrocytes; Disease Models, Animal; Enzyme Activation; Injections, Intra-Articular; JNK Mitogen-Activated Protein Kinases; Male; Membrane Potential, Mitochondrial; Nitric Oxide; Nitroprusside; Osteoarthritis; p38 Mitogen-Activated Protein Kinases; Rats, Sprague-Dawley | 2019 |
Tolerance of firocoxib in dogs with osteoarthritis during 90 days.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Creatinine; Dog Diseases; Dogs; Female; Male; Osteoarthritis; Sulfones; Treatment Outcome; Urea | 2011 |
Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis.
Topics: 4-Butyrolactone; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Female; Lameness, Animal; Male; Osteoarthritis; Prospective Studies; Severity of Illness Index; Sulfones; Treatment Outcome | 2011 |
[European symposium about osteoarthritis in a dog].
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Dog Diseases; Dogs; Europe; Osteoarthritis; Physical Therapy Modalities; Sulfones; Treatment Outcome | 2007 |
Switching NSAIDs in practice: insights from the Previcox (firocoxib) Experience Trial.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Databases, Factual; Dogs; Drug Administration Schedule; Osteoarthritis; Patient Selection; Research Design; Retrospective Studies; Sulfones; Veterinary Drugs | 2007 |